| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Institute for Immunology, Hannover Medical School, Hanover, Germany; and
Laboratory for Lipid Biochemistry and Protein Interactions, Department of Molecular Cell Biology, Katholieke Universiteit Leuven, Leuven, Belgium
Circulation of lymphocytes through peripheral lymphoid tissues as well as progenitor entry into the thymus and its output of mature T cells are critical for normal immune function. Egress of lymphocytes from both peripheral lymphoid organs and thymus is dependent on sphingosine 1-phosphate (S1P) gradients. S1P-lyase 1 (SGPL1) deficiency leads to accumulation of S1P in lymphoid tissues, which blocks lymphocyte egress and induces thymus atrophy. In this study, we investigated thymocyte development in SGPL1-deficient mice (SGPL1–/–), which exhibited postnatal discontinuation of early thymocytopoiesis starting at 2 wk after birth. SGPL–/– thymi showed a loss of developing thymocytes in the thymic cortex between 2 and 4 wk of age, whereas mature thymocytes accumulated in the medulla. Detailed analysis demonstrated a deficit in thymic early T cell progenitors (ETP) as the principal reason for discontinued thymocyte development. This developmental block was accompanied by accumulation of ceramides, resulting in enhanced apoptosis of developing T cells. Lack of immigration or settlement of ETP completely halted thymocyte development. We conclude that increased ceramide levels in the thymus of SGPL1–/– mice abrogate thymic development postnatally by enhanced thymocyte apoptosis and depletion of thymic ETP. Our findings indicate that potentially therapeutic immunosuppression by SGPL1 inhibition should benefit from monitoring ceramides to prevent their increase to apoptosis- inducing levels.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by the Emmy Noether Program of the German Research Foundation (Deutsche Forschungsgemeinschaft), Grants GR 1943/1-4 (to M.H.G.) and KR 2320/2-1 (to A.K.); the Deutsche Forschungsgemeinschaft Priority Program 1267 "Sphingolipids-Signals and Disease," Grant GR 1943/2-1 (to M.H.G.); and the Fonds Wetenschappelijk Onderzoek-Vlaanderen (Grants G.0405.02 and G.0581.09; to P.P.V.V., covering the fee for the generation of the chimeric SGPL1+/– mice by Lexicon Genetics).
2 The funders had no role in study design, data collection and analysis, decision to publish, or preparation of this manuscript.
3 C.W. and A.K. contributed equally to this work.
4 Address correspondence and reprint requests to Dr. Markus H. Gräler, Institute for Immunology, Hannover Medical School, OE 9422, Building K11, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. E-mail address: graeler.markus{at}mh-hannover.de
5 Abbreviations used in this paper: BM, bone marrow; Cer, ceramide; DOP, 4-deoxypyridoxine; DN, double negative; DP, double positive; ETP, early T cell progenitor; S1P, sphingosine 1-phosphate; SP, single positive; Sph, sphingosine; SGPL1, S1P-lyase 1; Flt3, Fms-like tyrosine kinase receptor 3; ETP, early T cell progenitor; S1P1, SP1 receptor type 1; SA, streptavidin; LC/MS/MS, liquid chromatography/mass spectrometry/mass spectrometry; ESI, electrospray ionization; 2-MEE, 2-(2-methoxyethoxy)ethanol; wt, wild type; DL4, Delta-like 4; AxV, annexin V; LSK, Lin–Sca-1+c-kithigh.
6 The online version of this article contains supplemental material.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
